top of page
Qubigen and US-Based Rio Pharmaceuticals Partner for AI-Enhanced Drug Design in Neurological Disease
Qubigen Pty Ltd is pleased to announce that it has entered into an agreement with Rio Pharmaceuticals , Inc., a San Francisco-based biotechnology company focused on developing imaging tracers for the diagnosis and staging of neurological disease. This agreement marks Rio’s first expansion into therapeutics, launching a multi-stage development program with Qubigen to develop novel small molecule therapeutics targeting a critical pathway in neurological diseases. Combining AI
Oct 23, 20252 min read
Qubigen CEO Dr. Jonathan Hall to Speak at SBEI25 on Federated AI for Global Health & Drug Design
Qubigen is pleased to share that its CEO, Dr. Jonathan Hall, will be a featured speaker at the upcoming Society for Bioinformatics and...
Oct 13, 20252 min read
Qubigen CEO Dr. Jonathan Hall to Speak at AusBiotech International Conference 2025
Qubigen is proud to announce that its CEO, Dr. Jonathan Hall, will be speaking at the AusBiotech International Conference 2025. This is...
Oct 10, 20252 min read
bottom of page